tirzepatide bone loss Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes in obese mice via gut microbial-related metabolites New research suggests that prolonged

While compounded medications are not FDA-approved, they are manufactured and verified to meet pharmaceutical-grade standards

Milder weight categories For patients in the lower BMI ranges who still qualify for medical weight-loss medication, the magnitude of weight loss needed may be in the range that an oral GLP-1 reliably delivers

The use of recombinant human growth hormone to protect against muscle weakness in patients undergoing anterior cruciate ligament reconstruction: A pilot, randomized placebo-controlled trial

Limit known reflux triggers like caffeine, chocolate, mint, and carbonated beverages, which relax the esophageal sphincter further